News
ABIO
--
0.00%
--
Atrial Fibrillation Competitive Landscape,2020: Emerging Therapies and Key pharma players involved
Feb 25, 2021 (AB Digital via COMTEX) -- "Atrial Fibrillation Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present...
ABNewswire · 02/25 23:49
3 Net-Net Working Capital Stocks
GuruFocus News · 02/16 22:07
3 Net-Net Working Capital Stocks
3 Net-Net Working Capital Stocks, Stocks: ATHA,ABIO,MTCR, release date:Feb 16, 2021
GuruFocus.com · 02/16 15:21
Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Simply Wall St. · 02/13 06:09
Atrial Fibrillation Drugs Industry Research Report 2021 by Type, Applications, Regions, Market Size Estimation and Forecast to 2025
The Express Wire · 01/27 09:22
Best Penny Stocks To Buy Right Now? 5 For Your January Watch List
Jan 19, 2021 (Penny Stocks via COMTEX) -- Penny Stocks Continue Captivating The Market If you look at the top 10 most active stocks in the market today by...
Penny Stocks · 01/19 20:47
The impact of COVID-19 on Atrial Fibrillation Drugs Market - Growth, Trends, Industry Outlook, Growth Opportunity, Business Growth And Forecast (2021 - 2026)
Jan 12, 2021 (The Expresswire) -- The Atrial Fibrillation Drugs market report provides a detailed analysis of global market size, regional and country-level...
The Express Wire · 01/12 05:45
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the first patients have been enrolled in ASPEN-COVID-19, ...
GlobeNewswire · 12/15/2020 13:30
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. * rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccines * rNAPc2 is the only novel compound being devel...
GlobeNewswire · 12/15/2020 13:30
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. * rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccines * rNAPc2 is the only novel compound being devel...
GlobeNewswire · 12/15/2020 13:30
ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders
ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00 a.m. MT, now will be held at the company's offices located at 10170 Church Ranch Way, Suite 100, Westminste...
GlobeNewswire · 12/09/2020 22:40
ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders
WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00 a.m. MT, now will be held at the company’s offices lo...
GlobeNewswire · 12/09/2020 22:40
ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders
GlobeNewswire · 12/09/2020 22:40
ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders
WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00 a.m. MT, now will be held at the company’s offices lo...
GlobeNewswire · 12/09/2020 22:40
ARCA Biopharma wins FDA Fast Track status for experimental COVID treatment
ARCA Biopharma (ABIO) jumped 5.5% in today's trade for its highest close in a month after saying it received Fast Track designation from the U.S. Food and Drug Administration for
Seekingalpha · 11/24/2020 03:15
ARCA Biopharma gets Fast Track designation for experimental COVID-19 treatment
Shares of ARCA Biopharma Inc. undefined gained 5.5% in trading on Monday after the company said it received a Fast-Track designation from the Food and Drug...
MarketWatch · 11/23/2020 17:28
ARCA Biopharma gets Fast Track designation for experimental COVID-19 treatment
Shares of ARCA Biopharma Inc. undefined gained 5.5% in trading on Monday after the company said it received a Fast-Track designation from the Food and Drug...
MarketWatch · 11/23/2020 17:28
ARCA Biopharma gets Fast Track designation for experimental COVID-19 treatment
Shares of ARCA Biopharma Inc. undefined gained 5.5% in trading on Monday after the company said it received a Fast-Track designation from the Food and Drug...
MarketWatch · 11/23/2020 17:28
ARCA Biopharma gets Fast Track designation for experimental COVID-19 treatment
Shares of ARCA Biopharma Inc. gained 5.5% in trading on Monday after the company said it received a Fast-Track designation from the Food and Drug Administration for its mid-stage experimental COVID-19 treatment. ARCA plans to launch a Phase 2b clinical tr...
MarketWatch · 11/23/2020 17:28
ARCA Biopharma gets Fast Track designation for experimental COVID-19 treatment
Shares of ARCA Biopharma Inc. undefined gained 5.5% in trading on Monday after the company said it received a Fast-Track designation from the Food and Drug...
MarketWatch · 11/23/2020 17:28
Webull provides a variety of real-time ABIO stock news. You can receive the latest news about ARCA BIOPHARMA through multiple platforms. This information may help you make smarter investment decisions.
About ABIO
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.